JPH0813734B2 - Cosmetic composition - Google Patents
Cosmetic compositionInfo
- Publication number
- JPH0813734B2 JPH0813734B2 JP2168786A JP16878690A JPH0813734B2 JP H0813734 B2 JPH0813734 B2 JP H0813734B2 JP 2168786 A JP2168786 A JP 2168786A JP 16878690 A JP16878690 A JP 16878690A JP H0813734 B2 JPH0813734 B2 JP H0813734B2
- Authority
- JP
- Japan
- Prior art keywords
- cyclodextrin
- fragrance
- cosmetics
- irritation
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002537 cosmetic Substances 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 29
- 229920000858 Cyclodextrin Polymers 0.000 claims description 43
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 20
- 239000003205 fragrance Substances 0.000 claims description 18
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 18
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 15
- 229960004853 betadex Drugs 0.000 claims description 14
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 11
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 9
- 239000001116 FEMA 4028 Substances 0.000 claims description 9
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 9
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 9
- 231100000475 skin irritation Toxicity 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 231100000017 mucous membrane irritation Toxicity 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000007794 irritation Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- -1 Polyoxyethylene Polymers 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019719 rose oil Nutrition 0.000 description 2
- 239000010666 rose oil Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【発明の詳細な説明】 [産業上の利用分野] 本発明はα−、β−およびγ−シクロデキストリンの
混合物を配合することにより皮膚および粘膜に対する刺
激を抑制した化粧料組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial field of application] The present invention relates to a cosmetic composition in which irritation to the skin and mucous membranes is suppressed by incorporating a mixture of α-, β- and γ-cyclodextrin.
[従来技術とその課題] 香料は化粧料に良好な使用感を与え、商品価値を左右
する重要な配合成分であり、また他の配合成分のベース
臭をカバーする作用、多少の静菌効果、および保存効果
があり、その配合は化粧料に必須である。また、界面活
性剤は化粧料の乳化を行う場合に必要である。[Prior Art and its Problems] Perfume is an important component that gives cosmetics a good feeling of use and influences the commercial value. In addition, the action of covering the base odor of other components, a slight bacteriostatic effect, It also has a preservative effect, and its formulation is essential for cosmetics. Further, the surfactant is necessary when emulsifying cosmetics.
化粧料の使用にあたり、配合された香料あるいは界面
活性剤(以下、香料等という)が単に皮膚や粘膜上に付
着している間は問題がないが、皮内に吸収されるとその
刺激により急性、慢性の一次刺激性皮膚炎、光毒性、ア
レルギー性もしくは光アレルギー性皮膚炎あるいは色素
異常などの副作用を起こす。従って、化粧料に配合する
香料等はその安全性に充分に検討して調合しなければな
らないが、皮膚の性質には個人差が大きく使用する人に
よっては皮膚刺激が生ずることがある。When using cosmetics, there is no problem as long as the compounded fragrance or surfactant (hereinafter referred to as fragrance) simply adheres to the skin or mucous membranes, but if absorbed into the skin, it will be acute due to its irritation. It causes side effects such as chronic primary irritant dermatitis, phototoxicity, allergic or photoallergic dermatitis, and pigment abnormalities. Therefore, the fragrance and the like to be added to cosmetics must be carefully studied for their safety, but there are large individual differences in the properties of the skin, and skin irritation may occur depending on the user.
かかる問題を解決するため特公昭59−10323号には、
化粧料にβ−シクロデキストリンを配合し、香料成分が
皮膚細胞と反応して刺激を与える前にこれと結合させ、
香料成分と皮膚細胞との反応を阻止した化粧料が開示さ
れている。しかしながら、β−シクロデキストリンは化
粧料中の溶解性が低く、その刺激緩和効果は充分でな
い。また、これとは別にメチル化したシクロデキストリ
ンを化粧料に用いることも提案されている(特開昭62−
62897号)が、化学修飾を行うためコストが非常に高
い。To solve this problem, Japanese Patent Publication No. 59-10323 discloses
Β-cyclodextrin is blended with cosmetics, and the perfume ingredients are combined with skin cells before they are stimulated by reacting with them,
Cosmetics in which a reaction between a fragrance ingredient and skin cells is prevented are disclosed. However, β-cyclodextrin has low solubility in cosmetics and its irritation-relieving effect is not sufficient. Separately, it has also been proposed to use methylated cyclodextrin in cosmetics (Japanese Patent Laid-Open No. 62-62-62).
No. 62897) is very expensive because it is chemically modified.
本発明の目的は、皮膚に対する刺激が少なく安全性の
高い化粧料を提供することにある。An object of the present invention is to provide a cosmetic composition which is less irritating to the skin and has high safety.
本発明者らはかかる問題点について種々検討を重ねた
ところ、意外にもα、βおよびγ−シクロデキストリン
の混合物(混合デキストリン)がβ−シクロデキストリ
ン単独の場合よりも高濃度で化粧料に溶解し得るとの知
見を得て本発明を完成した。The present inventors have made various studies on such problems, and surprisingly, a mixture of α, β and γ-cyclodextrin (mixed dextrin) is unexpectedly dissolved in cosmetics at a higher concentration than in the case of β-cyclodextrin alone. The present invention has been completed based on the finding that it is possible.
[課題を解決するための手段] 本発明は香料及び界面活性剤を含有する化粧料におい
て、α−シクロデキストリン50〜80重量%、β−シクロ
デキストリン15〜45重量%およびγ−シクロデキストリ
ン5〜20重量%の組成比を有するα−、β−およびγ−
シクロデキストリン混合物を0.05〜10重量%配合したこ
とを特徴とする皮膚および粘膜刺激を抑制した化粧料組
成物を提供するものである。[Means for Solving the Problems] The present invention provides a cosmetic containing a fragrance and a surfactant, wherein 50 to 80% by weight of α-cyclodextrin, 15 to 45% by weight of β-cyclodextrin and 5 to γ-cyclodextrin are contained. Α-, β- and γ- with a composition ratio of 20% by weight
Disclosed is a cosmetic composition containing 0.05 to 10% by weight of a cyclodextrin mixture, which suppresses skin and mucous membrane irritation.
本発明にて用いられる混合シクロデキストリンは、6
〜8個のグルコース(ブドウ糖)分子がα−1,4−グル
コシド結合で環状に連なった非還元性のマルトオリゴ糖
であり、バチルス属(Bacillus sp.)の微生物などが産
生するシクロデキストリン生成酵素(Cyclomylos Gluca
notransferase)を澱粉に作用させることにより得られ
る。該混合シクロデキストリンとしては、α−シクロデ
キストリン50〜80重量%、β−シクロデキストリン15〜
45重量%およびγ−シクロデキストリン5〜20重量%を
含有するものが特に好ましい。かかる混合デキストリン
は、従来一般に用いられているβ−シクロデキストリン
に比べて化粧料に対する溶解性が著しく高く、皮膚に対
する化粧料の刺激も大きく抑制される。混合シクロデキ
ストリン中、α−、β−、γ−各デキストリンの配合割
合が、前記範囲外であると化粧料に対する溶解性が低く
皮膚刺激抑制の効果が低下する。The mixed cyclodextrin used in the present invention is 6
-8 glucose (glucose) molecules are non-reducing maltooligosaccharides in which α-1,4-glucoside bonds are linked in a ring, and a cyclodextrin-forming enzyme produced by a microorganism of the genus Bacillus sp. Cyclomylos Gluca
It is obtained by acting notransferase) on starch. As the mixed cyclodextrin, α-cyclodextrin 50 to 80% by weight, β-cyclodextrin 15 to
Those containing 45% by weight and 5 to 20% by weight of γ-cyclodextrin are particularly preferred. Such a mixed dextrin has a significantly higher solubility in cosmetics than conventionally-used β-cyclodextrin, and irritation of the cosmetics to the skin is greatly suppressed. If the blending ratio of α-, β-, and γ-dextrin in the mixed cyclodextrin is out of the above range, the solubility in cosmetics is low and the effect of suppressing skin irritation is reduced.
本発明にて用いられるシクロデキストリンの水に対す
る溶解性を調べた結果を第1図に示す。第1図より明ら
かなごとく、10〜30℃の実用温度範囲においてα−シク
ロデキストリン(α−CD)、β−シクロデキストリン
(β−CD)、γ−シクロデキストリン(γ−CD)の各シ
クロデキストリン単独の溶解性よりも混合デキストリン
(混合CD;α:60%、β:30%、γ:10%)の溶解性ははる
かに高い。The results of examining the solubility of the cyclodextrin used in the present invention in water are shown in FIG. As is clear from FIG. 1, each cyclodextrin of α-cyclodextrin (α-CD), β-cyclodextrin (β-CD) and γ-cyclodextrin (γ-CD) in the practical temperature range of 10 to 30 ° C. The solubility of mixed dextrins (mixed CD; α: 60%, β: 30%, γ: 10%) is much higher than that of the single substances.
β−シクロデキストリンは水溶性が低く、また、ベン
ゼン環は安定に包接するが、脂肪酸を包接した場合は不
安定である。しかしながら、α、β、γ−シクロデキス
トリンを組み合わせたことにより、単独の場合に比べて
溶解性が相乗的に向上し、しかもより広い範囲の刺激物
質を包接することができるようになった結果、刺激抑制
効果が著しく向上したものと推定される。β-Cyclodextrin has low water solubility, and the benzene ring is stably included, but it is unstable when a fatty acid is included. However, by combining α, β, γ-cyclodextrin, the solubility is synergistically improved as compared with the case of alone, and as a result, it becomes possible to include a wider range of stimulants, It is estimated that the irritation suppression effect was significantly improved.
本発明の化粧料には、例えば、練歯磨、クリーム類、
ローション類、石鹸類、シャンプー類、乳液類など公知
の化粧料が包含される。The cosmetics of the present invention include, for example, toothpaste, creams,
Known cosmetics such as lotions, soaps, shampoos and emulsions are included.
シクロデキストリンの化粧料中の配合量は0.05〜10%
である。配合量が0.05%より少ないと刺激抑制効果がな
く、また10%を越えて配合しても効果は同じである。Cyclodextrin content in cosmetics is 0.05-10%
Is. If the blending amount is less than 0.05%, there is no irritation suppressing effect, and if the blending amount exceeds 10%, the effect is the same.
本発明の化粧料にはその種類に応じて各種の公知の成
分が配合されてよい。Various known components may be blended in the cosmetic of the present invention depending on the type.
本発明の化粧料を製造するには、シクロデキストリン
を水に溶解し、これに香料を加えてよく攪拌混合した液
を調製し、常法に従って他の成分を配合する。In order to produce the cosmetic of the present invention, cyclodextrin is dissolved in water, a fragrance is added to this, a well-mixed solution is prepared, and other components are blended according to a conventional method.
本発明の化粧料は、皮膚および粘膜の刺激を抑制する
ために従来のごとく香料あるいは界面活性剤の配合割合
を低減する必要がないので商品価値、効果、安定性を損
なわず、商品の性格、特徴づけ、使用感を充分満足させ
ることができ、その刺激抑制効果が高い。Since the cosmetics of the present invention do not need to reduce the compounding ratio of a fragrance or a surfactant in order to suppress the irritation of the skin and mucous membranes as in the conventional case, the commercial value, the effect and the stability are not impaired, and the product character, It can be fully characterized and used, and its irritation-suppressing effect is high.
[実施例] つぎに本発明を実施例および比較例にもとづきさらに
具体的に説明する。なお、実施例、比較例中、配合量は
重量%である。EXAMPLES Next, the present invention will be described more specifically based on Examples and Comparative Examples. In the examples and comparative examples, the blending amount is% by weight.
実施例1 (洗顔クリーム(クレンジングフォーム)) 次の処方により常法に従って洗顔クリームを調製し
た。Example 1 (Facial cleansing cream (cleansing foam)) A facial cleansing cream was prepared according to a conventional method according to the following formulation.
成 分 配合量 ステアリン酸 20.0 パルミチン酸 10.0 ミリスチン酸 12.0 ラウリン酸 4.0 オレイルアルコール 4.0 ポリオキシエチレン還元ラノリン 2.0 香料 0.8 パラオキシ安息香酸メチル 0.2 濃グリセリン 18.0 水酸化カリウム 7.0 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 2.0 精製水 残 部 計 100 実施例1の洗顔フォームについて、香料を変えた各試
料を用い眼粘膜刺激試験を実施した。試験は検眼して欠
陥のない体重2,200〜2,800gの日本白色家兎雌3羽ずつ
を用い、一方の眼に試料0.1mlを眼球表面に充分作用す
るように注入して行った。各ウサギの試料を注入しない
方の眼をそれぞれ対照とし、注入後1、2、3日後にハ
ンド・スリット・ランプで検眼し、ドレイズ[Draise,
J.H.「APPRISAL OF THE SAFETY OF CHEMICALS IN FOOD
S,DRUGS AND COSMETICS」、ASSOCIATION OF FDA OFFICI
ALS OF U.S.、51頁(1959年)]の採点法に従い採点し
て、刺激の程度を判定した。Ingredients Amount Stearic acid 20.0 Palmitic acid 10.0 Myristic acid 12.0 Lauric acid 4.0 Oleyl alcohol 4.0 Polyoxyethylene reduced lanolin 2.0 Fragrance 0.8 Methyl paraoxybenzoate 0.2 Concentrated glycerin 18.0 Potassium hydroxide 7.0 α, β, γ-Cyclodextrin mixture (α : 60%, β: 30%, γ: 10%) 2.0 Purified water balance 100 A cleansing foam of Example 1 was subjected to an eye mucous membrane irritation test using each sample in which the fragrance was changed. The test was performed by using three Japanese white rabbit females each having an optometry and having a defect-free weight of 2,200 to 2,800 g, and 0.1 ml of the sample was injected into one eye so that the surface of the eyeball was sufficiently acted. The eyes of each rabbit without injection were used as controls, and the eyes were examined with a hand slit lamp one, two, and three days after injection, and the Draise [Draise,
JH "APPRISAL OF THE SAFETY OF CHEMICALS IN FOOD
S, DRUGS AND COSMETICS '', ASSOCIATION OF FDA OFFICI
ALS OF US, p. 51 (1959)] was used to evaluate the degree of irritation.
香料には刺激性の高いシンナミックアルデヒドと刺激
性が普通であるローズオイルを用いた。結果を第1表に
示す。Highly stimulating cinnamic aldehyde and rose oil, which is usually irritating, were used as the fragrance. The results are shown in Table 1.
第1表に示すようにシクロデキストリン混合物を配合
することにより香料の刺激を完全に抑制されていること
がわかる。 As shown in Table 1, it can be seen that the stimulus of the fragrance is completely suppressed by blending the cyclodextrin mixture.
実施例2(シャンプー) 成 分 配合量 アルキル硫酸トリエタノールアミン(35%) 40. ヤシ油脂肪酸ジエタノールアミド 6.0 安息香酸ナトリウム 0.1 パラオキシ安息香酸メチル 0.2 l−メントール 0.4 香 料 0.3 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 2.0 精製水 残 部 計 100 実施例3(クリーム) 成 分 配合量 スクワラン 6.0 流動パラフィン 5.0 固形パラフィン 2.0 オリブ油 3.0 ステアリン酸 2.0 親油型モノステアリン酸グリセリン 2.5 モノステアリン酸ポリオキシエチレンソルビタン(20E.
O.) 1.5 トリエタノールアミン 0.5 ポリエチレングリコール400 5.0 パラオキシ安息香酸メチル 0.3 パラオキシ安息香酸プロピル 0.1 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 2.0 香 料 0.2 精製水 残 部 計 100 得られたクリームを用いて、人貼布テストを実施し
た。試験は各試料約0.05gをテストプラスターのリント
布に塗布し、成人男子20人の上腕内側部に48時間閉塞貼
付して行った。プラスターを剥離後、表皮上の残留試料
を70%アルコール含浸脱脂綿で除去し、除去30分後に貼
付部を肉眼観察して刺激の程度を以下の判定基準で判定
し、下式に基づいて皮膚障害指数(スコアー)を算出し
た。Example 2 (Shampoo) Composition Blend amount Alkyl sulfate triethanolamine (35%) 40. Coconut oil fatty acid diethanolamide 6.0 Sodium benzoate 0.1 Methyl paraoxybenzoate 0.2 l-Menthol 0.4 Perfume 0.3 α, β, γ-cyclo Dextrin mixture (α: 60%, β: 30%, γ: 10%) 2.0 Purified water balance 100 Example 3 (cream) Component content Squalane 6.0 Liquid paraffin 5.0 Solid paraffin 2.0 Olive oil 3.0 Stearic acid 2.0 Parent Oil type glyceryl monostearate 2.5 Polyoxyethylene sorbitan monostearate (20E.
O.) 1.5 Triethanolamine 0.5 Polyethylene glycol 400 5.0 Methyl paraoxybenzoate 0.3 Propyl paraoxybenzoate 0.1 α, β, γ-Cyclodextrin mixture (α: 60%, β: 30%, γ: 10%) 2.0 Fragrance 0.2 Purified water Residual total 100 A human patch test was conducted using the obtained cream. The test was carried out by applying about 0.05 g of each sample to the lint cloth of the test plaster and applying the blockage to the inner part of the upper arm of 20 adult males for 48 hours. After removing the plaster, the residual sample on the epidermis is removed with 70% alcohol-impregnated absorbent cotton, and 30 minutes after the removal, the applied part is visually inspected to determine the degree of irritation according to the following criteria, and skin damage based on the following formula. An index (score) was calculated.
−:変化なし ±:不明瞭な紅斑 +:明瞭な紅斑 ++:紅斑及び浮腫 但し、N−、N±、N+、N++は、各々判定−、±、
+、++の例数である。-: No change ±: Unclear erythema +: Clear erythema ++: Erythema and edema However, N-, N ±, N +, and N ++ are judgment −, ±, and
The numbers are + and ++.
香料は実施例1と同様のシンナミックアルデヒドおよ
びローズオイルを用いた。結果を第2表に示す。As the fragrance, the same cinnamic aldehyde and rose oil as in Example 1 were used. The results are shown in Table 2.
第2表に示すように、α、β、γ−シクロデキストリ
ン混合物配合のクリーム(試料No.8、10)はその香料の
刺激を抑制することがわかる。 As shown in Table 2, it can be seen that the cream containing the α, β, γ-cyclodextrin mixture (Sample Nos. 8 and 10) suppresses the stimulation of the fragrance.
実施例4(化粧水) 成 分 配合量 変性アルコール 11.0 ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.4 香 料 0.2 パラオキシ安息香酸エチル 0.1 1,3−ブチレングリコール 5.0 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 1.0 精製水 残 部 計 100 実施例5(リンス) 成 分 配合量 ポリオキシエチレン(20E.O.)オレイルエーテル 0.4 塩化ステアリルトリメチルアンモニウム 4.0 セタノール 2.5 2−オクチルドデカノール 1.0 1,3−ブチレングリコール 2.0 パラオキシ安息香酸メチル 0.1 クエン酸 0.1 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 1.0 精製水 残 部 計 100 実施例6(ヘアトニック) 成 分 配合量 ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.5 変性アルコール 55.0 ニコチン酸ベンジル 0.005 サリチル酸 0.2 パラオキシ安息香酸メチル 0.1 香 料 0.4 l−メトール 0.1 1,3−ブチレングリコール 2.0 グリチルリチン酸ジカリウム 0.2 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 2.5 精製水 残 部 計 100 得られたヘアトニックは−5℃、1ケ月間の放置でも
沈澱物、曇りは発生しなかった。Example 4 (Toner lotion) Composition Blend amount Denatured alcohol 11.0 Polyoxyethylene hydrogenated castor oil (40E.O.) 0.4 Perfume 0.2 Ethyl paraoxybenzoate 0.1 1,3-butylene glycol 5.0 α, β, γ-Cyclodextrin Mixture (α: 60%, β: 30%, γ: 10%) 1.0 Purified water balance 100 Example 5 (rinse) Component content Polyoxyethylene (20E.O.) oleyl ether 0.4 Stearyltrimethylammonium chloride 4.0 Cetanol 2.5 2-Octyldodecanol 1.0 1,3-butylene glycol 2.0 Methyl paraoxybenzoate 0.1 Citric acid 0.1 α, β, γ-Cyclodextrin mixture (α: 60%, β: 30%, γ: 10%) 1.0 Purified water Residual 100 Total Example 6 (Hairtonic) Component Content Polyoxyethylene hydrogenated castor oil (40E.O.) 0.5 Denatured alcohol 55.0 Benzyl nicotinate 0.005 Salicylic acid 0.2 para Methyl xybenzoate 0.1 Fragrance 0.4 l-Metol 0.1 1,3-butylene glycol 2.0 Dipotassium glycyrrhizinate 0.2 α, β, γ-Cyclodextrin mixture (α: 60%, β: 30%, γ: 10%) 2.5 Purification Water balance 100 Total The obtained hair tonic did not generate any precipitate or cloud even after left at -5 ° C for 1 month.
なお、α−、β−、γ−シクロデキストリン混合物の
配合量を各々0.01、0.05、0.1、0.5、1.0、1.5、2.0重
量%に変更した以外は同様の組成で7種のヘアトニック
を調製し、同様に−5℃で1ケ月間放置を行ったとこ
ろ、0.01重量%のものは沈澱が発生し、皮膚刺激性の評
価も不良であった。In addition, 7 types of hair tonics were prepared with the same composition except that the blending amounts of the α-, β-, and γ-cyclodextrin mixtures were changed to 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, and 2.0% by weight, respectively. Similarly, when it was allowed to stand for 1 month at -5 ° C, 0.01 wt% of the product caused precipitation, and the skin irritation was also poorly evaluated.
また、実施例6において混合シクロデキストリンを各
々α−、β−、γ−シクロデキストリン100%に変更し
た以外は同様の組成で化粧料を調製した。前記評価方法
により評価したところいずれも−5℃の放置において曇
り、沈澱を生じ、皮膚刺激性の評価も不良であった。Further, a cosmetic was prepared with the same composition except that the mixed cyclodextrin in Example 6 was changed to 100% of α-, β-, and γ-cyclodextrin, respectively. When evaluated by the above-mentioned evaluation methods, in all cases, clouding and precipitation occurred when left at -5 ° C, and the evaluation of skin irritation was also poor.
実施例7(ピールオフパック) 成 分 配合量 ポリビニルアルコール 14.0 エタノール 13.0 プロピレングリコール 5.0 ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.7 香 料 0.2 α,β,γ−シクロデキストリン混合物 (α:60%、β:30%、γ:10%) 2.5 精製水 残 部 計 100 [発明の効果] 本発明によれば、香料や界面活性剤の配合量を低減す
ることなく皮膚に対し刺激の少ない化粧料が得られ、商
品価値が高くかつ安定性に優れる。Example 7 (Peel-off pack) Component Blending amount Polyvinyl alcohol 14.0 Ethanol 13.0 Propylene glycol 5.0 Polyoxyethylene hydrogenated castor oil (60E.O.) 0.7 Fragrance 0.2 α, β, γ-cyclodextrin mixture (α: 60%, β: 30%, γ: 10%) 2.5 Purified water balance 100 [Effect of the invention] According to the present invention, a cosmetic which is less irritating to the skin without reducing the blending amount of the fragrance or the surfactant is provided. It is obtained and has high commercial value and excellent stability.
第1図はシクロデキストリンの溶解性を示すグラフであ
る。第2図はクリームベースと各試料の刺激性との差を
示すグラフである。FIG. 1 is a graph showing the solubility of cyclodextrin. FIG. 2 is a graph showing the difference between the cream base and the irritancy of each sample.
Claims (1)
おいて、α−シクロデキストリン50〜80重量%、β−シ
クロデキストリン15〜45重量%およびγ−シクロデキス
トリン5〜20重量%の組成比を有するα−、β−および
γ−シクロデキストリン混合物を0.05〜10重量%配合し
たことを特徴とする皮膚および粘膜刺激を抑制した化粧
料組成物。1. In a cosmetic containing a fragrance and a surfactant, the composition ratio of α-cyclodextrin of 50 to 80% by weight, β-cyclodextrin of 15 to 45% by weight and γ-cyclodextrin of 5 to 20% by weight is used. A cosmetic composition which suppresses skin and mucous membrane irritation, characterized in that 0.05 to 10% by weight of the α-, β- and γ-cyclodextrin mixture is blended.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2168786A JPH0813734B2 (en) | 1990-05-15 | 1990-06-26 | Cosmetic composition |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2-126285 | 1990-05-15 | ||
| JP12628590 | 1990-05-15 | ||
| JP2168786A JPH0813734B2 (en) | 1990-05-15 | 1990-06-26 | Cosmetic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0474107A JPH0474107A (en) | 1992-03-09 |
| JPH0813734B2 true JPH0813734B2 (en) | 1996-02-14 |
Family
ID=26462505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2168786A Expired - Fee Related JPH0813734B2 (en) | 1990-05-15 | 1990-06-26 | Cosmetic composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0813734B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885593A (en) * | 1995-09-28 | 1999-03-23 | The Andrew Jergens Company | Skin care composition including cyclodextrin materials and method for treating skin therewith |
| JPH1095725A (en) * | 1996-09-20 | 1998-04-14 | Noevir Co Ltd | Antibacterial low-stimulation cosmetic |
| CN1134249C (en) * | 1997-11-27 | 2004-01-14 | 株式会社资生堂 | Face pack |
| DE10039063A1 (en) * | 2000-08-10 | 2002-02-21 | Beiersdorf Ag | Cosmetic and dermatological preparation containing cyclodextrins for the removal of sebum |
| FR2838642B1 (en) * | 2002-04-22 | 2004-07-30 | Oreal | USE OF A CYCLODEXTRIN AS A NACRANT AND PEARL COMPOSITIONS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5341440A (en) * | 1976-09-24 | 1978-04-14 | Horiuchi Itarou Shiyouten Kk | Deodorant |
| JPS5910323A (en) * | 1982-07-09 | 1984-01-19 | Shintou Dasutokorekutaa Kk | Dust collecting device |
| JPS638309A (en) * | 1986-06-26 | 1988-01-14 | Ichimaru Pharcos Co Ltd | Bathing agent or cosmetic, dissolved in use and containing clathrate of aromatic essential oil component |
| JPS63280010A (en) * | 1987-05-12 | 1988-11-17 | Sekisui Chem Co Ltd | Plaster for preventing armpit odor |
-
1990
- 1990-06-26 JP JP2168786A patent/JPH0813734B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0474107A (en) | 1992-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4707293A (en) | Detergent composition | |
| KR101217382B1 (en) | EXTERNAL DERMATOLOGICAL FORMULATION COMPRISING SACCHARIDE DERIVATIVE OF α,α-TREHALOSE | |
| JP4205226B2 (en) | Cell activator, skin external preparation and skin cleansing agent containing the same | |
| KR0159271B1 (en) | Cosmetics containing inclusion product with hydroxyalkylated cyclodextrin and powder cosmetics thereof | |
| JPH0552806B2 (en) | ||
| EP1957168A2 (en) | Glucan compositions | |
| DE2408663A1 (en) | THIXOTROPIC EMULSIONS WITH A HIGH CONTENT IN THE INNER PHASE AND THEIR USE | |
| EP2322138A2 (en) | Antimicrobial composition | |
| JP2007505093A (en) | Skin care compositions and methods | |
| DE3586194T2 (en) | BIOEMULGATORS CONTAINING COSMETIC AND PHARMACEUTICAL COMPOSITIONS. | |
| JPH0393707A (en) | Oil-in-water type emulsion cosmetic | |
| JPH0859450A (en) | Topical skin | |
| US2460776A (en) | Bacteriostatic base for medicinal, cosmetic, and toilet preparations | |
| JPH0813734B2 (en) | Cosmetic composition | |
| JPH0532556A (en) | Skin agent for external use | |
| JPH03236305A (en) | Cosmetic | |
| JPH0725660B2 (en) | Cosmetics with anti-inflammatory properties against sunburn | |
| JPS6112799A (en) | Detergent | |
| JPH01283206A (en) | Toiletry product blended with lysozyme chloride | |
| JP2002145719A (en) | Cosmetic material | |
| JP3912722B2 (en) | Topical skin preparation | |
| JPH11180832A (en) | Composition for scalp and hair | |
| JPH03291207A (en) | Dermatic agent for external use | |
| JPH10279427A (en) | Moisture-retaining cosmetic material composition | |
| JP2017193504A (en) | Deodorant cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090214 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090214 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100214 Year of fee payment: 14 |
|
| LAPS | Cancellation because of no payment of annual fees |